Clinical trial
A Phase II Trial of Stereotactic Body Radiotherapy With Concurrent Anti-PD1 Treatment in Metastatic Melanoma.
NCT02821182 is registered in ClinicalTrials.gov with University Hospital, Ghent as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Trial of Stereotactic Body Radiotherapy With Concurrent Anti-PD1 Treatment in Metastatic Melanoma.
- Lead sponsor
- University Hospital, Ghent
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 1, 2016
- Completion date
- December 31, 2019
- Enrollment
- 20 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.